Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed AML
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04905407 |
|
Recruitment Status :
Recruiting
First Posted : May 27, 2021
Last Update Posted : February 27, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Tamibarotene is being studied as a treatment for participants with a type of leukemia called acute myeloid leukemia, or AML for short. Tamibarotene is being studied as a treatment for participants with AML whose cancer has a specific genetic abnormality characterized by the overexpression of the retinoic acid receptor alpha (RARA) gene. This genetic profile is found in about 3 of every 10 people with AML.
During the trial, tamibarotene will be given with 2 other drugs that are already used together to treat people who have AML and who cannot start treatment with standard chemotherapy.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Acute Myeloid Leukemia | Drug: Tamibarotene Drug: Venetoclax Drug: Azacitidine | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 95 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Tamibarotene in Combination With Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-positive AML Who Are Ineligible for Standard Induction Therapy |
| Actual Study Start Date : | August 26, 2021 |
| Estimated Primary Completion Date : | April 2024 |
| Estimated Study Completion Date : | April 2024 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Part 1: Tamibarotene/Venetoclax/Azacitidine
Participants will receive the tamibarotene/venetoclax/azacitidine triplet combination as follows: Azacitidine (intravenously or subcutaneously) at 75 milligrams (mg)/square meter (m^2) once daily, on Days 1 through 7 of each 28-day therapy cycle (per VIDAZA USPI). Alternative dosing of azacitidine (Days 1 through 5, 8, and 9) will be permitted throughout the study. Venetoclax (orally) daily on Days 1 through 28 per standard of care. Standard of care daily dosing is 100 mg on Day 1, 200 mg on Day 2, and 400 mg on Day 3 and beyond. Tamibarotene 6 mg twice daily (BID) orally, on Days 8 through 28 of each 28-day therapy cycle. Tamibarotene will only be administered to participants who have been confirmed as RARA-positive. |
Drug: Tamibarotene
Tamibarotene tablets will be administered per dose and schedule specified in the arm. Drug: Venetoclax Venetoclax tablets will be administered per dose and schedule specified in the arm.
Other Name: Venclexta Drug: Azacitidine Azacitidine injection will be administered per dose and schedule specified in the arm.
Other Name: Vidaza |
|
Experimental: Part 2: Tamibarotene/Venetoclax/Azacitidine
Participants will receive the tamibarotene/venetoclax/azacitidine triplet combination at the dose and regimen selected in Part 1.
|
Drug: Tamibarotene
Tamibarotene tablets will be administered per dose and schedule specified in the arm. Drug: Venetoclax Venetoclax tablets will be administered per dose and schedule specified in the arm.
Other Name: Venclexta Drug: Azacitidine Azacitidine injection will be administered per dose and schedule specified in the arm.
Other Name: Vidaza |
|
Active Comparator: Part 2: Venetoclax/Azacitidine
Participants will receive the venetoclax/azacitidine combination at the dose and regimen selected in Part 1.
|
Drug: Venetoclax
Venetoclax tablets will be administered per dose and schedule specified in the arm.
Other Name: Venclexta Drug: Azacitidine Azacitidine injection will be administered per dose and schedule specified in the arm.
Other Name: Vidaza |
|
Experimental: Part 3: Tamibarotene/Venetoclax/Azacitidine
Part 2 participants treated with venetoclax/azacitidine who experience progressive disease, relapse after initial CR or CRi response, or treatment failure may begin subsequent treatment in Part 3, where tamibarotene will be added to their regimen.
|
Drug: Tamibarotene
Tamibarotene tablets will be administered per dose and schedule specified in the arm. Drug: Venetoclax Venetoclax tablets will be administered per dose and schedule specified in the arm.
Other Name: Venclexta Drug: Azacitidine Azacitidine injection will be administered per dose and schedule specified in the arm.
Other Name: Vidaza |
- Part 1: Number of Participants With Adverse Events [ Time Frame: up to 3 years ]
- Part 2: CR/CRi Rate [ Time Frame: up to 3 years ]CR/CRi rate is estimated by the proportion of participants who achieve CR/CRi (as determined by the investigator).
- Part 1: Overall Response Rate (ORR) [ Time Frame: up to 3 years ]Overall response assessment is comprised of CR, CRi, CR with partial hematologic recovery (CRh), morphologically leukemia-free state (MLFS), or partial remission (PR) (as determined by the investigator). ORR is estimated by the proportion of participants who achieve overall response.
- Part 1: Plasma Concentration of Tamibarotene [ Time Frame: Day 8 and 22 of Cycle 1, Day 15 of Cycles 2 and 3 (cycle length = 28 days) ]
- Part 2: Number of Participants With Adverse Events [ Time Frame: up to 3 years ]
- Part 2: CR Rate [ Time Frame: up to 3 years ]CR rate is estimated by the proportion of participants who achieve CR (as determined by the investigator).
- Part 2: CR/CRh Rate [ Time Frame: up to 3 years ]CR/CRh rate is estimated by the proportion of participants who achieve CR/CRh (as determined by the investigator).
- Part 2: Duration of CR [ Time Frame: up to 3 years ]Duration of CR is defined as duration from the date of first documented evidence of CR to the date of relapse of disease (as determined by the investigator), or death due to any cause, whichever occurs first.
- Part 2: Duration of CR/CRi [ Time Frame: up to 3 years ]Duration of CR/CRi is defined as duration from the date of first documented evidence of CR/CRi to the date of relapse of disease (as determined by the investigator), or death due to any cause, whichever occurs first.
- Part 2: Duration of CR/CRh [ Time Frame: up to 3 years ]Duration of CR/CRh is defined as duration from the date of first documented evidence of CR/CRh to the date of relapse of disease (as determined by the investigator), or death due to any cause, whichever occurs first.
- Part 2: Time to CR [ Time Frame: up to 3 years ]Time to CR is defined as the duration from the date of Cycle 1 Day 1 Visit to the date of the first documented evidence of CR as determined by the investigator.
- Part 2: Time to CR/CRi [ Time Frame: up to 3 years ]Time to CR/CRi is defined as the duration from the date of Cycle 1 Day 1 Visit to the date of the first documented evidence of CR/CRi as determined by the investigator.
- Part 2: Time to CR/CRh [ Time Frame: up to 3 years ]Time to CR/CRh is defined as the duration from the date of Cycle 1 Day 1 Visit to the date of the first documented evidence of CR/CRh as determined by the investigator.
- Part 2: ORR [ Time Frame: up to 3 years ]Overall response assessment is comprised of CR, CRi, CRh, MLFS, or PR (as determined by the investigator). ORR is estimated by the proportion of participants who achieve overall response.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Note: all inclusion/exclusion criteria should be met prior to the first dose of venetoclax/azacitidine on Cycle 1 Day 1 with the exception of the RARA-biomarker test result referenced in inclusion criterion 2, which should be positive by Cycle 1 Day 8 to continue treatment on study.
Inclusion Criteria:
- All participants must have obtained a blood sample for RARA biomarker investigational assay testing prior to starting treatment on Cycle 1 Day 1. The results of the investigational biomarker assay for all participants must be confirmed as RARA-positive by Cycle 1 Day 8 to enroll (Part 1) or to be randomized (Part 2) in the study.
-
Participants must have newly diagnosed, previously untreated non-acute promyelocytic leukemia (APL) AML with a bone marrow or peripheral blood blast count ≥20% and must be unlikely to tolerate standard intensive chemotherapy at the time of Cycle 1 Day 1 Visit due to age, performance status, or comorbidities based on at least one of the following criteria:
- age ≥75 years old, or
-
age <75 years old, with at least one of the following:
- Eastern Cooperative Oncology Group (ECOG) performance status of 3
- cardiac history of congestive heart failure (CHF) or documented ejection fraction (EF) ≤50%
- pulmonary disease with diffusing capacity of the lungs for carbon monoxide (DLCO) ≤65% or forced expiratory volume in one second (FEV1) ≤65%
- creatinine clearance ≥30 milliliters (mL)/minute (min) to <45 mL/min based on the Cockcroft-Gault glomerular filtration rate estimation
- hepatic impairment with total bilirubin >1.5 to ≤3.0 * upper limit of normal (ULN)
- any other comorbidity that the investigator judges to be incompatible with intensive chemotherapy, and reviewed and approved by the sponsor.
Exclusion Criteria:
- Participants have APL.
- Participants have known active central nervous system involvement with AML.
- Prior treatment (before Cycle 1 Day 1) for the diagnosis of AML, myelodysplastic syndromes (MDS), or antecedent hematologic malignancy with any hypomethylating agent, venetoclax, chemotherapy, or hematopoietic stem cell transplantation (HSCT), with the exception of prior treatment with hydroxyurea.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04905407
| Contact: Kim Caliri Director, Clinical Operations | 617-674-9053 | kcaliri@syros.com | |
| Contact: Erica Warlick Medical Director, MD | 617-865-2108 | ewarlick@syros.com |
Show 26 study locations
| Study Director: | Michael Kelly Executive Medical Director, MD | Syros Pharmaceuticals |
| Responsible Party: | Syros Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT04905407 |
| Other Study ID Numbers: |
SY-1425-202 |
| First Posted: | May 27, 2021 Key Record Dates |
| Last Update Posted: | February 27, 2023 |
| Last Verified: | December 2022 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Azacitidine Venetoclax Antimetabolites, Antineoplastic Antimetabolites |
Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Enzyme Inhibitors |